rituximab + CHOP

Phase 2Terminated
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AIDS Related Lymphoma

Conditions

AIDS Related Lymphoma

Trial Timeline

Jan 1, 1999 → Oct 1, 2003

About rituximab + CHOP

rituximab + CHOP is a phase 2 stage product being developed by Roche for AIDS Related Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00126243. Target conditions include AIDS Related Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00126243Phase 2Terminated